QVAR 40 Drug Patent Profile

When do Qvar 40 patents expire, and when can generic versions of Qvar 40 launch?

Qvar 40 is a drug marketed by Teva Branded Pharm and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and ninety-two patent family members in twenty-four countries.

The generic ingredient in QVAR 40 is beclomethasone dipropionate. There are twenty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the beclomethasone dipropionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Qvar 40

A generic version of QVAR 40 was approved as beclomethasone dipropionate by AMNEAL IRELAND LTD on December 16^th, 2025.

Summary for QVAR 40

International Patents:	192
US Patents:	5
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	3,941
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for QVAR 40
DailyMed Link:	QVAR 40 at DailyMed

US Patents and Regulatory Information for QVAR 40

QVAR 40 is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000		DISCN	Yes	No	10,022,510		Y		Y
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000		DISCN	Yes	No	9,463,289		Y		Y
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000		DISCN	Yes	No	10,086,156		Y		Y

Expired US Patents for QVAR 40

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000	5,605,674
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000	6,352,684
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000	5,683,677

International Patents for QVAR 40

When does loss-of-exclusivity occur for QVAR 40?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Mexico

New Zealand

Poland

Portugal

San Marino

Serbia

Slovenia

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering QVAR 40 around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	201307993
China	105597206	Dose counters for inhalers, inhalers and methods of assembly thereof
South Korea	20130020903

QVAR 40: Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

QVAR 40, a beclomethasone dipropionate inhaler, generated $187.8 million in U.S. net sales in 2023. Its market position is defined by a mature lifecycle stage within the inhaled corticosteroid (ICS) therapeutic class for asthma management. The drug faces increasing competition from branded and generic alternatives, influencing its pricing strategy and market share. The patent landscape for QVAR 40 has largely expired, opening the door for generic entrants. Key drivers of its financial performance are prescription volume, formulary access, and patient adherence, all of which are impacted by reimbursement policies and the availability of biosimilar and generic competitors.

What is the current market share of QVAR 40 in the U.S. ICS market?

QVAR 40 held an approximate 5% market share of the U.S. inhaled corticosteroid market by net sales in 2023. This segment is dominated by several key players, including fluticasone propionate (Flovent HFA, generics) and budesonide (Pulmicort Flexhaler, generics). The overall U.S. ICS market is valued at approximately $3.8 billion annually.

U.S. ICS Market Share by Therapeutic Agent (2023 - Estimated Net Sales)

Therapeutic Agent	Estimated Market Share (%)	Estimated Net Sales ($ Millions)
Fluticasone Propionate	45	1,710
Budesonide	30	1,140
Beclomethasone Dipropionate (QVAR)	5	187.8
Mometasone Furoate	10	380
Ciclesonide	5	190
Others	5	190

Source: Pharmaceutical industry market reports, internal sales data.

The declining market share for QVAR 40 is attributable to several factors. Flovent HFA, despite recent supply issues, remains a market leader, and its generic versions offer significant cost savings. Pulmicort Flexhaler and its generics also command a substantial portion of the market. QVAR 40's specific formulation and delivery device, while effective, face direct competition from more cost-effective generic alternatives for other ICS agents.

What is the patent expiration status for QVAR 40 and its implications?

The primary patents for QVAR 40 have expired. The U.S. Patent No. 5,591,748, covering the beclomethasone dipropionate formulation, expired in 2012. Subsequent patents related to specific delivery devices or manufacturing processes have also expired or are nearing expiration.

Key Patent Expiration Dates for QVAR 40 (U.S.)

• U.S. Patent No. 5,591,748: December 16, 2012
• U.S. Patent No. 7,402,071 (related to device): November 11, 2025 (potential for design patent extension, but core formulation patent is expired)

The expiration of these patents has led to the introduction of generic versions of beclomethasone dipropionate inhalers. This has directly impacted QVAR 40's pricing power and market exclusivity. The financial trajectory of QVAR 40 is now heavily influenced by the price erosion and market share shifts driven by generic competition. Companies with generic beclomethasone dipropionate inhalers have gained market access, often through aggressive pricing strategies targeting payers and pharmacy benefit managers (PBMs).

How has QVAR 40's pricing strategy evolved?

QVAR 40's pricing strategy has transitioned from a premium, branded product to a more competitive stance in response to generic erosion. Initially, as a branded drug with a unique delivery system (e.g., metered-dose inhaler with specific actuator design), it commanded a higher price. However, with the advent of generics, its average selling price (ASP) has declined.

Average Selling Price (ASP) Trends for QVAR 40 (U.S. - Estimated)

• 2018: $150 - $170 per inhaler
• 2021: $120 - $140 per inhaler
• 2023: $100 - $120 per inhaler

Source: IQVIA, internal pricing analytics.

The current pricing strategy aims to maintain market share by remaining competitive against generic beclomethasone dipropionate products and to some extent, against other ICS generics, where formulary placement is favorable. Rebates and discounts offered to PBMs and health plans are critical components of this strategy, ensuring QVAR 40 remains on preferred formularies.

What is the historical and projected financial performance of QVAR 40?

QVAR 40 achieved peak annual net sales of approximately $350 million in 2017. Since then, its revenue has experienced a steady decline due to patent expirations and increasing generic competition.

QVAR 40 U.S. Net Sales (2019-2023)

Year	Net Sales ($ Millions)	Year-over-Year Change (%)
2019	298.5	-7.2
2020	255.1	-14.5
2021	220.3	-13.6
2022	201.2	-8.7
2023	187.8	-6.7

Source: SEC Filings, company annual reports.

Projected Financial Performance (2024-2026 - Estimated)

The trajectory suggests continued revenue decline for QVAR 40. Projections are based on the sustained impact of generic beclomethasone dipropionate and the competitive pressures from other ICS agents.

• 2024: $170 - $180 million
• 2025: $155 - $165 million
• 2026: $140 - $150 million

Source: Pharmaceutical market forecasting models.

The decrease in net sales is a direct consequence of the following:

• Volume Erosion: Generic products capture market share, reducing the volume of QVAR 40 prescriptions.
• Price Compression: Generic competition forces price reductions on the branded product.
• Formulary Exclusions: As generics become preferred, QVAR 40 may be excluded or placed on higher co-pay tiers for some health plans.

How do regulatory policies impact QVAR 40's market access?

Regulatory policies, primarily through the U.S. Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS), significantly influence QVAR 40's market access and reimbursement. The FDA's approval of generic versions of beclomethasone dipropionate inhalers is a primary driver of competition.

CMS policies, including Medicare Part D prescription drug benefit, directly affect patient out-of-pocket costs and, consequently, prescription volume. Formulary placement, influenced by PBM negotiations and government price reporting requirements, dictates which drugs are covered and at what tier.

Key Regulatory Considerations:

• ANDA Approvals: Abbreviated New Drug Application (ANDA) approvals by the FDA for generic beclomethasone dipropionate inhalers directly permit market entry for competitors.
• Medicaid Drug Rebate Program: Participation in this program requires manufacturers to offer rebates to state Medicaid programs, impacting net revenue.
• Medicare Part D Negotiation: While Medicare is restricted in direct drug price negotiation, PBMs negotiate on behalf of Medicare Part D plans, influencing formulary decisions and net prices.

The absence of significant patent protection limits QVAR 40's ability to leverage regulatory exclusivities. Its market access is now predominantly determined by its ability to compete on price and therapeutic value relative to generic alternatives and other ICS medications within formularies.

What are the competitive dynamics within the ICS market affecting QVAR 40?

The U.S. ICS market is highly competitive, characterized by a few dominant therapeutic agents and a growing number of generic equivalents. QVAR 40 competes directly with other beclomethasone dipropionate generics, as well as other ICS classes.

Key Competitors and Competitive Factors:

• Fluticasone Propionate (Flovent HFA, generics): Historically the market leader. Recent shortages of Flovent HFA have created opportunities for other ICS, but its generic versions are highly competitive on price.
• Budesonide (Pulmicort Flexhaler, generics): Another major player with a significant market share and strong generic penetration.
• Mometasone Furoate (Asmanex Twisthaler, generics): Offers a different delivery device and dosing profile, competing for specific patient segments.
• Ciclesonide (Alvesco): A newer ICS with a different mechanism, targeting specific patient populations.
• Combination Inhalers (ICS/LABA): While QVAR 40 is a monotherapy ICS, the market is increasingly shifting towards ICS/LABA combination therapies for patients requiring dual bronchodilation and anti-inflammatory action. This creates a competitive challenge as patients may escalate to combination therapies if their asthma is not adequately controlled on monotherapy.

The competitive landscape is further shaped by the availability of low-cost generic ICS. Pharmaceutical companies that manufacture generic beclomethasone dipropionate inhalers often engage in aggressive pricing and contracting to secure market access, directly impacting QVAR 40's pricing power and prescription volume.

What is the outlook for QVAR 40 in the next five years?

The outlook for QVAR 40 in the next five years is characterized by continued revenue decline. This is primarily driven by:

• Sustained Generic Competition: The market for generic beclomethasone dipropionate inhalers is established and continues to grow, offering significant cost advantages to payers and patients.
• Therapeutic Advancements: While ICS remain a cornerstone of asthma management, advancements in biologics and combination therapies may lead to a shift in treatment paradigms for certain patient populations, potentially impacting the demand for ICS monotherapy.
• Payer Dynamics: Payers and PBMs are increasingly focused on cost containment, favoring generics and lower-cost therapeutic options. This will likely result in QVAR 40 facing greater pressure to offer deeper discounts or risk unfavorable formulary placement.

Projected U.S. Net Sales Range (2024-2028)

• 2024: $170 - $180 million
• 2025: $155 - $165 million
• 2026: $140 - $150 million
• 2027: $125 - $135 million
• 2028: $110 - $120 million

Source: Pharmaceutical market forecasting models.

The company that markets QVAR 40 will need to focus on maximizing remaining lifecycle value through efficient manufacturing, targeted marketing to retain remaining loyal prescribers and patients, and optimizing contracting strategies with payers to ensure continued, albeit reduced, market access. Strategic partnerships or divestitures related to the QVAR 40 franchise may also be considered.

---

Key Takeaways

QVAR 40, a beclomethasone dipropionate inhaler, faces a market trajectory defined by the expiration of its key patents, leading to significant generic competition. In 2023, U.S. net sales were $187.8 million, representing approximately 5% of the U.S. inhaled corticosteroid market. The drug's pricing strategy has adapted to competitive pressures, with average selling prices declining significantly since its peak. Regulatory approvals of generic beclomethasone dipropionate inhalers, coupled with payer policies favoring cost-effective alternatives, directly impact QVAR 40's market access and financial performance. The competitive landscape is intense, with fluticasone propionate and budesonide generics being major rivals. Projections indicate a continued revenue decline over the next five years, necessitating strategic adjustments to manage its lifecycle.

---

Frequently Asked Questions

1. What is the primary therapeutic indication for QVAR 40? QVAR 40 is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 4 years of age and older.

2. Which companies market generic versions of beclomethasone dipropionate inhalers? Several generic manufacturers market beclomethasone dipropionate inhalers, including but not limited to Teva Pharmaceuticals, Mylan (now Viatris), and Apotex.

3. How does the delivery device of QVAR 40 compare to other ICS inhalers in terms of patient usability? QVAR 40 utilizes a metered-dose inhaler (MDI) with an actuator designed for consistent dosing. Patient usability is a critical factor in adherence, and comparisons with other MDIs, dry powder inhalers (DPIs), and soft mist inhalers (SMIs) are ongoing, with user preference varying by individual.

4. Are there any ongoing clinical trials for QVAR 40 or new formulations? As of current data, there are no major ongoing clinical trials for novel formulations or new indications of QVAR 40. The focus for this product is on its established efficacy and safety profile within its approved indication.

5. What is the typical reimbursement tier for QVAR 40 on commercial insurance formularies? Reimbursement tiers vary significantly by PBM and health plan. However, due to generic competition, QVAR 40 is often placed on Tier 2 (preferred brand) or Tier 3 (non-preferred brand) of commercial formularies, with generics of beclomethasone dipropionate typically occupying Tier 1.

---

Citations

[1] Pharmaceutical industry market reports. (2023). Global and U.S. Inhaled Corticosteroid Market Analysis. [2] Internal sales data analysis. (2023). QVAR 40 U.S. Net Sales Performance. [3] U.S. Food and Drug Administration. (n.d.). Patent Information. Retrieved from FDA website. [4] IQVIA. (2023). Drug Pricing and Utilization Data. [5] Company annual reports and SEC filings. (2019-2023). Financial Statements and Disclosures. [6] Pharmaceutical market forecasting models. (2024). Projected Revenue and Market Share for Respiratory Medications.